PURPOSE: There has been an increase in the incidence of rectal cancer diagnosed in young adults (age < 50 years). We evaluated outcomes among young adults treated with pre-operative long course chemoradiation (CRT) and total mesorectal excision (TME). METHODS: The medical records of 219 patients, age 18-49, with non-metastatic, cT3-4, or cN1-2 rectal adenocarcinoma treated from 2000 to 2017 were reviewed for demographic and treatment characteristics, as well as pathologic and oncologic outcomes. The Kaplan-Meier test, log-rank test, and Cox regression analysis were used to evaluate survival outcomes. RESULTS: The median age at diagnosis was 44 years. CRT followed by TME and post-operative chemotherapy was the most frequent treatment sequence (n = 196), with FOLFOX (n = 115) as the predominant adjuvant chemotherapy. There was no difference in sex, stage, MSS/pMMR, or pCR by age (< 45 years [n = 111] vs. ≥ 45 years [n = 108]). The 5-year rates of DFS were 77.2% for all patients, 69.8% for age < 45 years and 84.7% for age ≥ 45 years (P = .01). The 5-year rates of OS were 89.6% for all patients, 85.1% for patients with age < 45 years and 94.3% for patients with age ≥ 45 years (P = .03). Age ≥ 45 years was associated with a lower risk of disease recurrence or death on multivariable Cox regression analysis (HR = 0.55, 95% CI 0.31-0.97, P = .04). CONCLUSION: Among young adults, patients with age < 45 years had lower rates of DFS and OS, compared to those with age ≥ 45 years. These outcomes could serve as a benchmark by which to evaluate newer treatment approaches.
PURPOSE: There has been an increase in the incidence of rectal cancer diagnosed in young adults (age < 50 years). We evaluated outcomes among young adults treated with pre-operative long course chemoradiation (CRT) and total mesorectal excision (TME). METHODS: The medical records of 219 patients, age 18-49, with non-metastatic, cT3-4, or cN1-2 rectal adenocarcinoma treated from 2000 to 2017 were reviewed for demographic and treatment characteristics, as well as pathologic and oncologic outcomes. The Kaplan-Meier test, log-rank test, and Cox regression analysis were used to evaluate survival outcomes. RESULTS: The median age at diagnosis was 44 years. CRT followed by TME and post-operative chemotherapy was the most frequent treatment sequence (n = 196), with FOLFOX (n = 115) as the predominant adjuvant chemotherapy. There was no difference in sex, stage, MSS/pMMR, or pCR by age (< 45 years [n = 111] vs. ≥ 45 years [n = 108]). The 5-year rates of DFS were 77.2% for all patients, 69.8% for age < 45 years and 84.7% for age ≥ 45 years (P = .01). The 5-year rates of OS were 89.6% for all patients, 85.1% for patients with age < 45 years and 94.3% for patients with age ≥ 45 years (P = .03). Age ≥ 45 years was associated with a lower risk of disease recurrence or death on multivariable Cox regression analysis (HR = 0.55, 95% CI 0.31-0.97, P = .04). CONCLUSION: Among young adults, patients with age < 45 years had lower rates of DFS and OS, compared to those with age ≥ 45 years. These outcomes could serve as a benchmark by which to evaluate newer treatment approaches.
Authors: Andrew M D Wolf; Elizabeth T H Fontham; Timothy R Church; Christopher R Flowers; Carmen E Guerra; Samuel J LaMonte; Ruth Etzioni; Matthew T McKenna; Kevin C Oeffinger; Ya-Chen Tina Shih; Louise C Walter; Kimberly S Andrews; Otis W Brawley; Durado Brooks; Stacey A Fedewa; Deana Manassaram-Baptiste; Rebecca L Siegel; Richard C Wender; Robert A Smith Journal: CA Cancer J Clin Date: 2018-05-30 Impact factor: 508.702
Authors: Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2020-03-05 Impact factor: 508.702
Authors: Emmanouil Fokas; Michael Allgäuer; Bülent Polat; Gunther Klautke; Gerhard G Grabenbauer; Rainer Fietkau; Thomas Kuhnt; Ludger Staib; Thomas Brunner; Anca-Ligia Grosu; Wolff Schmiegel; Lutz Jacobasch; Jürgen Weitz; Gunnar Folprecht; Anke Schlenska-Lange; Michael Flentje; Christoph-Thomas Germer; Robert Grützmann; Matthias Schwarzbach; Vittorio Paolucci; Wolf O Bechstein; Tim Friede; Michael Ghadimi; Ralf-Dieter Hofheinz; Claus Rödel Journal: J Clin Oncol Date: 2019-05-31 Impact factor: 44.544
Authors: Joshua E Meyer; Steven J Cohen; Karen J Ruth; Elin R Sigurdson; Michael J Hall Journal: J Natl Cancer Inst Date: 2016-01 Impact factor: 13.506
Authors: Andrew Kolarich; Thomas J George; Steven J Hughes; Daniel Delitto; Carmen J Allegra; William A Hall; George J Chang; Sanda A Tan; Christiana M Shaw; Atif Iqbal Journal: Cancer Date: 2018-07-09 Impact factor: 6.860
Authors: Renu R Bahadoer; Esmée A Dijkstra; Boudewijn van Etten; Corrie A M Marijnen; Hein Putter; Elma Meershoek-Klein Kranenbarg; Annet G H Roodvoets; Iris D Nagtegaal; Regina G H Beets-Tan; Lennart K Blomqvist; Tone Fokstuen; Albert J Ten Tije; Jaume Capdevila; Mathijs P Hendriks; Ibrahim Edhemovic; Andrés Cervantes; Per J Nilsson; Bengt Glimelius; Cornelis J H van de Velde; Geke A P Hospers Journal: Lancet Oncol Date: 2020-12-07 Impact factor: 41.316
Authors: In Ja Park; Y Nancy You; Atin Agarwal; John M Skibber; Miguel A Rodriguez-Bigas; Cathy Eng; Barry W Feig; Prajnan Das; Sunil Krishnan; Christopher H Crane; Chung-Yuan Hu; George J Chang Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544